TapewireFind a company

person · Reporting owner

Guiheen Lawrence P.

Disclosed activity across 1 company

Tapewire entity
59868
SEC CIK
0001554353

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
ADMA BIOLOGICS, INC.ADMA · Entity 4477DirectorMarch 13, 2026March 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ADMA BIOLOGICS, INC.

Report date March 13, 2026 · Filed March 18, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect105,520 Last balance in matching sequence After 2026-03-17 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 1 · 2026-03-13 · Exercise / conversion · Acquired 30,000 · Balance 135,520

F1: Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; and (ii) 94,830 shares of common stock owned by the Reporting Person.

Row 2 · 2026-03-17 · Gift · Disposed 30,000 · Balance 105,520

F2: This transaction involved the Reporting Person's gift of 30,000 shares of Issuer common stock to the Lawrence P Guiheen Irrevocable Trust DTD 9/20/19, Arlene Guiheen TTEE, Katherine M Guiheen TTEE (the "2019 Guiheen Irrevocable Trust"), over which Mr. Guiheen retains control. The Reporting Person disclaims beneficial ownership of the securities held by the 2019 Guiheen Irrevocable Trust, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

F1: Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; and (ii) 94,830 shares of common stock owned by the Reporting Person.

Common StockSEC Table I · non-derivativeIndirectSee footnote30,000 Reported balance After 2026-03-17 transaction · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · 2026-03-17 · Gift · Acquired 30,000 · Balance 30,000

F2: This transaction involved the Reporting Person's gift of 30,000 shares of Issuer common stock to the Lawrence P Guiheen Irrevocable Trust DTD 9/20/19, Arlene Guiheen TTEE, Katherine M Guiheen TTEE (the "2019 Guiheen Irrevocable Trust"), over which Mr. Guiheen retains control. The Reporting Person disclaims beneficial ownership of the securities held by the 2019 Guiheen Irrevocable Trust, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

F3: Includes 30,000 shares of common stock held in the 2019 Guiheen Irrevocable Trust.

Common StockSEC Table I · non-derivativeIndirectSee footnote50,990 Reported balance Holding disclosure · report date 2026-03-13 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 50,990

F4: Includes 50,990 shares of common stock held in the Lawrence P Guiheen Irrevocable Trust 1.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.66 · Expires 2027-06-06Direct23,837 Reported balance After 2026-03-13 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2026-03-13 · Exercise / conversion · Disposed 30,000 · Balance 23,837

F5: The Reporting Person is exercising this option due, in part, to its near-term expiration date.

F6: These options vested in twenty-four equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; and (ii) 94,830 shares of common stock owned by the Reporting Person.

F2: This transaction involved the Reporting Person's gift of 30,000 shares of Issuer common stock to the Lawrence P Guiheen Irrevocable Trust DTD 9/20/19, Arlene Guiheen TTEE, Katherine M Guiheen TTEE (the "2019 Guiheen Irrevocable Trust"), over which Mr. Guiheen retains control. The Reporting Person disclaims beneficial ownership of the securities held by the 2019 Guiheen Irrevocable Trust, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

F3: Includes 30,000 shares of common stock held in the 2019 Guiheen Irrevocable Trust.

F4: Includes 50,990 shares of common stock held in the Lawrence P Guiheen Irrevocable Trust 1.

F5: The Reporting Person is exercising this option due, in part, to its near-term expiration date.

F6: These options vested in twenty-four equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
March 17, 2026 Filed Mar 18, 2026 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GiftCommon Stock 30,000 $0.00 $0.00
Disclosure

SEC source: 0001140361-26-009900 · form4.xml · nonDerivative · entry 3

Guiheen Lawrence P. · CIK 0001554353 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 30,000

F2 · kind: This transaction involved the Reporting Person's gift of 30,000 shares of Issuer common stock to the Lawrence P Guiheen Irrevocable Trust DTD 9/20/19, Arlene Guiheen TTEE, Katherine M Guiheen TTEE (the "2019 Guiheen Irrevocable Trust"), over which Mr. Guiheen retains control. The Reporting Person disclaims beneficial ownership of the securities held by the 2019 Guiheen Irrevocable Trust, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

F3 · ownership.nature: Includes 30,000 shares of common stock held in the 2019 Guiheen Irrevocable Trust.

Read SEC document
March 17, 2026 Filed Mar 18, 2026 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GiftCommon Stock 30,000 $0.00 $0.00
Disclosure

SEC source: 0001140361-26-009900 · form4.xml · nonDerivative · entry 2

Guiheen Lawrence P. · CIK 0001554353 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,520

F2 · kind: This transaction involved the Reporting Person's gift of 30,000 shares of Issuer common stock to the Lawrence P Guiheen Irrevocable Trust DTD 9/20/19, Arlene Guiheen TTEE, Katherine M Guiheen TTEE (the "2019 Guiheen Irrevocable Trust"), over which Mr. Guiheen retains control. The Reporting Person disclaims beneficial ownership of the securities held by the 2019 Guiheen Irrevocable Trust, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

F1 · balance_after: Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; and (ii) 94,830 shares of common stock owned by the Reporting Person.

Read SEC document
March 13, 2026 Filed Mar 18, 2026 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionStock Option (Right to Buy) · Derivative 30,000 $0.00 Strike: $3.66 $0.00
Disclosure

SEC source: 0001140361-26-009900 · form4.xml · derivative · entry 5

Guiheen Lawrence P. · CIK 0001554353 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,837

Underlying: Common Stock · 30,000 shares

Expires 2027-06-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · shares: The Reporting Person is exercising this option due, in part, to its near-term expiration date.

F6 · derivative.exercise_date: These options vested in twenty-four equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.

Read SEC document
March 13, 2026 Filed Mar 18, 2026 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 30,000 $3.66 $109,800.00
Disclosure

SEC source: 0001140361-26-009900 · form4.xml · nonDerivative · entry 1

Guiheen Lawrence P. · CIK 0001554353 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 135,520

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; and (ii) 94,830 shares of common stock owned by the Reporting Person.

Read SEC document
February 09, 2026 Filed Feb 12, 2026 02:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantStock Option (Right to Buy) · Derivative 17,730 $0.00 Strike: $16.37 $0.00
Disclosure

SEC source: 0001140361-26-004886 · form4.xml · derivative · entry 3

Guiheen Lawrence P. · CIK 0001554353 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,730

Underlying: Common Stock · 17,730 shares

Expires 2036-02-09

F4 · derivative.exercise_date: These options vest in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.

Read SEC document
February 09, 2026 Filed Feb 12, 2026 02:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantCommon Stock 10,690 $0.00 $0.00
Disclosure

SEC source: 0001140361-26-004886 · form4.xml · nonDerivative · entry 1

Guiheen Lawrence P. · CIK 0001554353 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,520

F1 · shares: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date.

F2 · balance_after: Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; (ii) 5,445 RSUs out of 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the Reporting Person's continued service as of such vesting date; and (iii) 89,385 shares of common stock owned by the Reporting Person.

Read SEC document
June 09, 2025 Filed Jun 12, 2025 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 SaleCommon Stock 20,000 $20.96 $419,200.00
Disclosure

SEC source: 0001140361-25-022240 · form4.xml · nonDerivative · entry 1

Guiheen Lawrence P. · CIK 0001554353 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 94,830

F1 · balance_after: Includes, as of the transaction date, (i) 10,889 restricted stock units granted on February 19, 2025, which vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of such vesting date; and (ii) 83,941 shares of common stock owned by the Reporting Person.

Read SEC document
May 22, 2025 Filed May 24, 2025 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionStock Option (right to buy) · Derivative 1,221 $0.00 Strike: $5.96 $0.00
Disclosure

SEC source: 0001140361-25-020376 · form4.xml · derivative · entry 7

Guiheen Lawrence P. · CIK 0001554353 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,221 shares

Expires 2026-01-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · shares: The Reporting Person is exercising this option due, in part, to its near-term expiration date.

F6 · derivative.exercise_date: These options were granted on January 28, 2016 and vested in twenty-four equal monthly installments, becoming fully vested on January 28, 2018.

Read SEC document
May 22, 2025 Filed May 24, 2025 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 SaleCommon Stock 1,221 $20.12 $24,566.52
Disclosure

SEC source: 0001140361-25-020376 · form4.xml · nonDerivative · entry 4

Guiheen Lawrence P. · CIK 0001554353 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 114,830

F2 · balance_after: Includes, as of the transaction date, (i) 10,889 restricted stock units granted on February 19, 2025, which vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of such vesting date; and (ii) 103,941 shares of common stock owned by the Reporting Person. The number of common shares reported includes a de minimis reduction by 10 shares from the amount previously reported due to a broker adjustment.

Read SEC document
May 22, 2025 Filed May 24, 2025 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 1,221 $5.96 $7,277.16
Disclosure

SEC source: 0001140361-25-020376 · form4.xml · nonDerivative · entry 3

Guiheen Lawrence P. · CIK 0001554353 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,051

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 21, 2025 Filed May 24, 2025 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionStock Option (right to buy) · Derivative 7,779 $0.00 Strike: $5.96 $0.00
Disclosure

SEC source: 0001140361-25-020376 · form4.xml · derivative · entry 6

Guiheen Lawrence P. · CIK 0001554353 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,221

Underlying: Common Stock · 7,779 shares

Expires 2026-01-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · shares: The Reporting Person is exercising this option due, in part, to its near-term expiration date.

F6 · derivative.exercise_date: These options were granted on January 28, 2016 and vested in twenty-four equal monthly installments, becoming fully vested on January 28, 2018.

Read SEC document
May 21, 2025 Filed May 24, 2025 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 SaleCommon Stock 7,779 $20.32 $158,069.28
Disclosure

SEC source: 0001140361-25-020376 · form4.xml · nonDerivative · entry 2

Guiheen Lawrence P. · CIK 0001554353 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 114,830

F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.20 to $20.73. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

Read SEC document
May 21, 2025 Filed May 24, 2025 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 7,779 $5.96 $46,362.84
Disclosure

SEC source: 0001140361-25-020376 · form4.xml · nonDerivative · entry 1

Guiheen Lawrence P. · CIK 0001554353 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 122,609

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 19, 2025 Filed Feb 22, 2025 02:05 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantStock Option (right to buy) · Derivative 16,279 $0.00 Strike: $16.07 $0.00
Disclosure

SEC source: 0001140361-25-005542 · form4.xml · derivative · entry 3

Guiheen Lawrence P. · CIK 0001554353 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,279

Underlying: Common Stock · 16,279 shares

Expires 2035-02-19

F4 · derivative.exercise_date: The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.

Read SEC document
February 19, 2025 Filed Feb 22, 2025 02:05 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantCommon Stock 10,889 $0.00 $0.00
Disclosure

SEC source: 0001140361-25-005542 · form4.xml · nonDerivative · entry 1

Guiheen Lawrence P. · CIK 0001554353 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 164,830

F1 · shares: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date.

F2 · balance_after: Includes, as of the transaction date, (i) 10,889 RSUs granted on February 19, 2025 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 12,020 restricted stock units granted on February 26, 2024, which will vest fully on February 26, 2025, subject to the Reporting Person's continued service as of such vesting date; and (iii) 141,921 shares of common stock owned by the Reporting Person.

Read SEC document
September 09, 2024 Filed Sep 12, 2024 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock · Derivative 9,000 $10.80 Strike: $10.80 $97,200.00
Disclosure

SEC source: 0001140361-24-040872 · form4.xml · derivative · entry 4

Guiheen Lawrence P. · CIK 0001554353 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,000 shares

Expires 2025-01-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · shares: The Reporting Person is exercising these options due, in part, to their near-term expiration date.

F4 · derivative.exercise_date: These options were granted on January 30, 2015 and vested in twenty-four equal monthly installments, becoming fully vested on January 30, 2017.

Read SEC document
September 09, 2024 Filed Sep 12, 2024 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 SaleCommon Stock 9,000 $18.47 $166,188.60
Disclosure

SEC source: 0001140361-24-040872 · form4.xml · nonDerivative · entry 2

Guiheen Lawrence P. · CIK 0001554353 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 153,941

F1 · price: The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $18.465 to $18.47. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

F2 · balance_after: Includes, as of the transaction date, (i) 12,020 restricted stock units granted on February 26, 2024, which will vest fully on February 26, 2025, subject to the Reporting Person's continued service as of such vesting date; and (ii) 141,921 shares of common stock owned by the Reporting Person.

Read SEC document
September 09, 2024 Filed Sep 12, 2024 01:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 9,000 $10.80 $97,200.00
Disclosure

SEC source: 0001140361-24-040872 · form4.xml · nonDerivative · entry 1

Guiheen Lawrence P. · CIK 0001554353 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 162,941

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 26, 2024 Filed Feb 29, 2024 02:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantStock Option (right to buy) · Derivative 37,541 $0.00 Strike: $5.40 $0.00
Disclosure

SEC source: 0001140361-24-010240 · form4.xml · derivative · entry 3

Guiheen Lawrence P. · CIK 0001554353 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,541

Underlying: Common Stock · 37,541 shares

Expires 2034-02-26

F4 · derivative.exercise_date: The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.

Read SEC document
February 26, 2024 Filed Feb 29, 2024 02:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantCommon Stock 24,040 $0.00 $0.00
Disclosure

SEC source: 0001140361-24-010240 · form4.xml · nonDerivative · entry 1

Guiheen Lawrence P. · CIK 0001554353 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 153,941

F1 · shares: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date.

F2 · balance_after: Includes, as of the transaction date, (i) 24,040 RSUs granted on February 26, 2024 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 25,815 RSUs granted on March 6, 2023 which will vest in full on March 6, 2024; and (iii) 104,086 shares of common stock owned by the reporting person.

Read SEC document
March 06, 2023 Filed Mar 9, 2023 02:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantEmployee Stock Option (right to buy) · Derivative 51,630 $0.00 Strike: $3.35 $0.00
Disclosure

SEC source: 0001140361-23-010770 · form4.xml · derivative · entry 3

Guiheen Lawrence P. · CIK 0001554353 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,630

Underlying: Common Stock · 51,630 shares

Expires 2033-03-06

F4 · derivative.exercise_date: The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.

Read SEC document
March 06, 2023 Filed Mar 9, 2023 02:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantCommon Stock 25,815 $0.00 $0.00
Disclosure

SEC source: 0001140361-23-010770 · form4.xml · nonDerivative · entry 1

Guiheen Lawrence P. · CIK 0001554353 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 129,901

F1 · shares: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date.

F2 · balance_after: Includes, as of the transaction date, (i) 25,815 RSUs granted on March 6, 2023 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 13,293 RSUs granted on March 7, 2022, which will vest in full on March 7, 2023; and (iii) 90,793 shares of common stock owned by the reporting person.

Read SEC document
March 07, 2022 Filed Mar 9, 2022 22:59 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantEmployee Stock Option (right to buy) · Derivative 53,172 $0.00 Strike: $1.67 $0.00
Disclosure

SEC source: 0001140361-22-008675 · form4.xml · derivative · entry 3

Guiheen Lawrence P. · CIK 0001554353 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,172

Underlying: Common Stock · 53,172 shares

Expires 2032-03-07

F4 · derivative.exercise_date: The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.

Read SEC document
March 07, 2022 Filed Mar 9, 2022 22:59 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantCommon Stock 26,586 $0.00 $0.00
Disclosure

SEC source: 0001140361-22-008675 · form4.xml · nonDerivative · entry 1

Guiheen Lawrence P. · CIK 0001554353 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,086

F1 · shares: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date.

F2 · balance_after: Includes (i) 26,586 RSUs granted on March 7, 2022 and reported on this Form 4, subject to vesting as set forth in footnote (1); and (ii) 77,500 shares of common stock owned by the reporting person.

Read SEC document
February 25, 2021 Filed Mar 2, 2021 02:04 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantStock Option (right to buy) · Derivative 55,000 $0.00 Strike: $2.35 $0.00
Disclosure

SEC source: 0001193805-21-000297 · e620332_4-guiheen.xml · derivative · entry 1

Guiheen Lawrence P. · CIK 0001554353 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2031-02-25

F1 · derivative.exercise_date: The options vest in twelve equal monthly installments, becoming fully vested on February 25, 2022.

Read SEC document
February 28, 2020 Filed Mar 4, 2020 00:10 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantEmployee Stock Option (right to buy) · Derivative 15,000 $0.00 Strike: $2.92 $0.00
Disclosure

SEC source: 0001193805-20-000289 · e619423_4-guiheen.xml · derivative · entry 3

Guiheen Lawrence P. · CIK 0001554353 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-02-28

F4 · derivative.exercise_date: The option vests in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.

Read SEC document
February 28, 2020 Filed Mar 4, 2020 00:10 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantCommon Stock 7,500 $0.00 $0.00
Disclosure

SEC source: 0001193805-20-000289 · e619423_4-guiheen.xml · nonDerivative · entry 1

Guiheen Lawrence P. · CIK 0001554353 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,500

F1 · shares: These shares represent restricted stock units ("RSUs"), which will vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting.

F2 · balance_after: Includes (i) 7,500 RSUs granted on February 28, 2020 and reported on this Form 4, subject to vesting as set forth in footnote (1) and will be settled into common stock upon vesting; and (ii) 70,000 shares of common stock owned by the reporting person.

Read SEC document
February 28, 2020 Filed May 1, 2020 21:10 UTC Amendment ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantCommon Stock 7,500 $0.00 $0.00
Disclosure

SEC source: 0001193805-20-000550 · e619596_4a-guiheen.xml · nonDerivative · entry 1

Guiheen Lawrence P. · CIK 0001554353 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,500

F1 · shares: These shares represent restricted stock units ("RSUs"). Subsequent to the filing of the initial Form 4 by the Reporting Person on March 3, 2020, the Board of Directors of the Issuer corrected the vesting schedule of the RSUs. The RSUs will vest in two equal installments, on the six- and 12-month anniversaries of the grant, becoming fully vested on the one-year anniversary of the grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting.

F2 · balance_after: Includes (i) 7,500 RSUs granted on February 28, 2020 and reported on this Form 4, subject to vesting as set forth in footnote (1) and will be settled into common stock upon vesting; and (ii) 70,000 shares of common stock owned by the reporting person.

Read SEC document
February 11, 2020 Filed Feb 11, 2020 15:18 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 20,000 $3.50 $70,000.00
Disclosure

SEC source: 0001193805-20-000135 · e619337_4-guiheen.xml · nonDerivative · entry 1

Guiheen Lawrence P. · CIK 0001554353 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,000

F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering.

Read SEC document
May 17, 2019 Filed May 21, 2019 11:13 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 25,000 $4.00 $100,000.00
Disclosure

SEC source: 0001193805-19-000523 · e618482_4-guiheen.xml · nonDerivative · entry 1

Guiheen Lawrence P. · CIK 0001554353 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering.

Read SEC document
March 13, 2019 Filed Mar 15, 2019 21:02 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantStock Option (right to buy) · Derivative 30,000 $0.00 Strike: $3.89 $0.00
Disclosure

SEC source: 0001193805-19-000297 · e618307_4-guiheen.xml · derivative · entry 1

Guiheen Lawrence P. · CIK 0001554353 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2029-03-13

F1 · derivative.exercise_date: The option vests in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.

F2 · derivative.expiration_date: The option terminates on the earlier of (i) March 13, 2029 and (ii) the one-year anniversary of the reporting person's ceasing to serve as a director of the Issuer.

Read SEC document
June 22, 2018 Filed Jun 25, 2018 21:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantStock Option (right to buy) · Derivative 17,500 $0.00 Strike: $4.91 $0.00
Disclosure

SEC source: 0001193805-18-000902 · e618127_4-guiheen.xml · derivative · entry 1

Guiheen Lawrence P. · CIK 0001554353 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2028-06-22

F1 · derivative.exercise_date: The option vests in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant.

F2 · derivative.expiration_date: The option terminates on the earlier of (i) June 22, 2028 and (ii) the one year anniversary of the reporting person's ceasing to serve as a director of the Issuer.

Read SEC document
June 08, 2018 Filed Jun 11, 2018 11:09 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 20,000 $4.78 $95,600.00
Disclosure

SEC source: 0001193805-18-000819 · e618085_4-guiheen.xml · nonDerivative · entry 1

Guiheen Lawrence P. · CIK 0001554353 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering.

Read SEC document
June 06, 2017 Filed Jun 8, 2017 22:04 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantStock Option (right to buy) · Derivative 53,837 $0.00 Strike: $3.66 $0.00
Disclosure

SEC source: 0001193805-17-001060 · e616267_4-guiheen.xml · derivative · entry 1

Guiheen Lawrence P. · CIK 0001554353 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,837

Underlying: Common Stock · 53,837 shares

Expires 2027-06-06

F1 · derivative.exercise_date: The option vests in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant.

F2 · derivative.expiration_date: The option terminates on the earlier of (i) June 6, 2027 and (ii) the one year anniversary of the reporting person's ceasing to serve as a director of the Issuer.

Read SEC document
February 14, 2017 Filed Feb 17, 2017 01:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantStock Option (right to buy) · Derivative 10,000 $0.00 Strike: $5.00 $0.00
Disclosure

SEC source: 0001193805-17-000282 · e615795_4-guiheen.xml · derivative · entry 1

Guiheen Lawrence P. · CIK 0001554353 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2027-02-14

F1 · derivative.exercise_date: The option vests in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant.

F2 · derivative.expiration_date: The option terminates on the earlier of (i) February 14, 2027 and (ii) the one year anniversary of the reporting person's ceasing to serve as a director of the Issuer.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.